Show simple item record

dc.contributor.authorKim, W. S.
dc.contributor.authorOki, Y.
dc.contributor.authorKim, S. J.
dc.contributor.authorYoon, S. E.
dc.contributor.authorArdeshna, K. M.
dc.contributor.authorLin, Y.
dc.contributor.authorRuan, J.
dc.contributor.authorPorcu, P.
dc.contributor.authorBrammer, J. E.
dc.contributor.authorJacobsen, E. D.
dc.contributor.authorYoon, D. H.
dc.contributor.authorSuh, C.
dc.contributor.authorSuarez, F.
dc.contributor.authorRadford, John A
dc.contributor.authorBudde, L. E.
dc.contributor.authorKim, J. S.
dc.contributor.authorBachy, E.
dc.contributor.authorLee, H. J.
dc.contributor.authorBollard, C. M.
dc.contributor.authorJaccard, A.
dc.contributor.authorKang, H. J.
dc.contributor.authorInman, S.
dc.contributor.authorMurray, M.
dc.contributor.authorCombs, K. E.
dc.contributor.authorLee, D. Y.
dc.contributor.authorAdvani, R.
dc.contributor.authorGunter, K. C.
dc.contributor.authorRooney, C. M
dc.contributor.authorHeslop, H. E.
dc.date.accessioned2021-08-17T12:22:46Z
dc.date.available2021-08-17T12:22:46Z
dc.date.issued2021en
dc.identifier.citationKim WS, Oki Y, Kim SJ, Yoon SE, Ardeshna KM, Lin Y, et al. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Ann Hematol. 2021 Jul 24.en
dc.identifier.pmid34304287en
dc.identifier.doi10.1007/s00277-021-04558-0en
dc.identifier.urihttp://hdl.handle.net/10541/624457
dc.description.abstractWe conducted a phase II clinical trial to develop an autologous EBV-specific T cell product (baltaleucel T) for advanced, relapsed ENKTL. Among 47 patients who provided whole blood starting material for manufacturing the product, 15 patients received a median of 4 doses of baltaleucel T. Thirty-two (68%) patients did not receive baltaleucel-T due to manufacturing failure, rapid disease progression, and death. Of the 15 patients, 10 patients had measurable disease at baseline (salvage cohort), and 5 patients had no disease at baseline assessment (adjuvant cohort). In the 15 patients, the median follow-up duration was 10.2 months (range 2.0-23.5 months), median progression-free survival (PFS) was 3.9 months, and the median overall survival (OS) was not reached. Patients in the salvage cohort achieved a 30% complete response (CR) and a 50% overall response rate (ORR). In the adjuvant cohort, disease progression was reported in three patients and two patients did not relapse during study follow-up. When we compared survival outcomes of seven responders and eight non-responders, the PFS (P = 0.001) and OS (P = 0.014) of responders proved statistically superior to that of non-responders. Baltaleucel-T was well tolerated. We have performed a phase II clinical trial of autologous EBV-specific T cell treatment (baltaleucel-T) in R/R ENKTL. Autologous EBV-specific T cells were well tolerated and demonstrated single-agent activity in R/R ENTKL.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1007/s00277-021-04558-0en
dc.titleAutologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter studyen
dc.typeArticleen
dc.contributor.departmentDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, South Korea.en
dc.identifier.journalAnnals of Hematologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record